1. Factor Xa Inhibitors in Coronary Artery Disease

3. Targets of Antithrombotic Agents

4. EUCLID Ticagrelor vs Clopidogrel for PAD

5. COMPASS Selected Exclusion Criteria

6. COMPASS Inclusion Criteria

7. COMPASS Efficacy Outcomes

8. ATLAS ACS 2 -- TIMI 51 Rivaroxaban vs Placebo After ACS

9. ATLAS ACS-TIMI 46 Dose-Escalation Study in Patients After ACS

10. ATLAS ACS 2 -- TIMI 51 Bleeding Outcomes

11. COMPASS CAD and PAD Cohorts

12. COMPASS Background Therapy

13. COMPASS Patients with CAD and PAD

14. COMPASS Stroke Outcomes

15. REACH Registry CV Event Rates in Stable Outpatients at Risk of or With Atherothrombosis

16. COMPASS PAD Cohort Peripheral Limb Outcomes

17. Clinical Applicability of COMPASS

18. Current and Future Antithrombotic Regimens

19. Clinical Applicability of COMPASS

20. Efficacy of Antithrombotic Secondary Prevention in Stable Vascular Disease

21. Comparison of Guideline-Indicated Secondary Prevention Therapies and CV Risk Reduction

22. COMPASS Bleeding Outcomes

23. COMPASS CAD Cohort Analysis of Major Bleeding

24. External Applicability of the COMPASS Trial REACH Registry

25. Potential Candidates for Rivaroxaban Therapy

26. COMPASS PAD Cohort Patients Who Benefited From Therapy

27. Correct Dose of Rivaroxaban

28. Summary

29. Abbreviations

30. Abbreviations (cont)